Busca avançada
Ano de início
Entree


The Crystal Structure of the Plasmodium falciparum PdxK Provides an Experimental Model for Pro-Drug Activation

Texto completo
Autor(es):
Gao, Kai ; Wang, Wenjia ; Kronenberger, Thales ; Wrenger, Carsten ; Groves, Matthew R.
Número total de Autores: 5
Tipo de documento: Artigo Científico
Fonte: CRYSTALS; v. 9, n. 10, p. 11-pg., 2019-10-01.
Resumo

Pyridoxine/pyridoxal kinase (PdxK), belongs to the ribokinase family and is involved in the vitamin B6 salvage pathway by phosphorylating 5-pyridoxal (PL) into an active form. In the human malaria parasite, Plasmodium falciparum, PfPdxK functions to salvage vitamin B6 from both itself and its host. Here, we report the crystal structure of PfPdxK from P. falciparum in complex with a non-hydrolyzable ATP analog (AMP-PNP) and PL. As expected, the fold is retained and both AMP-PNP and PL occupy the same binding sites when compared to the human ortholog. However, our model allows us to identify a FIxxIIxL motif at the C terminus of the disordered repeat motif (XNXH)(m) that is implicated in binding the WD40 domain and may provide temporal control of PfPdxK through an interaction with a E3 ligase complex. Furthermore, molecular docking approaches based on our model allow us to explain differential PfPdxK phosphorylation and activation of a novel class of potent antimalarials (PT3, PT5 and PHME), providing a basis for further development of these compounds. Finally, the structure of PfPdxK provides a high-quality model for a better understanding of vitamin B6 synthesis and salvage in the parasite. (AU)

Processo FAPESP: 17/03966-4 - Alvejando a via de recuperação e biossíntese de ácido lipoico em MRSA
Beneficiário:Carsten Wrenger
Modalidade de apoio: Auxílio à Pesquisa - Regular
Processo FAPESP: 14/03644-9 - Sítios de interação alternativos em receptores nucleares e sua viabilidade como alvos terapêuticos usando triagem computacional e experimental
Beneficiário:Thales Kronenberger
Modalidade de apoio: Bolsas no Brasil - Doutorado
Processo FAPESP: 15/26722-8 - Drug discovery contra doenças infecciosas humanos
Beneficiário:Carsten Wrenger
Modalidade de apoio: Auxílio à Pesquisa - Temático